Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


National Advertising Division In Brief

This article was originally published in The Tan Sheet

Executive Summary

NAD scrutinizes Colostrum-LD claims

You may also be interested in...

Burner Balm clinical results unveiled

Pacific Shore Holdings' lip balm infused with dietary supplement ingredients for weight management "performed better than anyone expected," says David Toomey, lead investigator in a 12-week, double-blind, placebo-controlled clinical trial involving more than 100 subjects. Los Angeles-based Pacific Shore noted participants using Burner Balm lost an average of seven to nine pounds, many reporting consumption of smaller meals and elimination of snacks. The firm claims the balm's energy-boosting green tea, appetite-suppressing hoodia gordonii, chromium picolinate and caffeine absorb "faster and steadier into the bloodstream" by traveling through blood vessels in the lips. Launching soon to retailers worldwide, Burner Balm sticks are available online at $5.99 apiece

Bankruptcy Court Gives Green Light To Akorn Sale

Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.

Dr Reddy’s Enters OTC Eyecare Space

Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts